Strategic License Agreement to Advance Novel Cancer Therapy

In a move to significantly strengthen its oncology pipeline, Bayer AG has secured an exclusive global license from Suzhou Puhe Biopharma, a Chinese biotechnology firm. This agreement grants Bayer the rights to develop, manufacture, and commercialize a promising PRMT5 inhibitor, designated Bay3713372, targeting specific solid tumors. Financial details of the licensing agreement remain undisclosed.

Targeting MTAP-Deficient Tumors: A Promising Avenue

The core focus of this therapeutic approach lies in addressing tumors exhibiting MTAP deficiencies. Bayer’s research indicates that MTAP loss is prevalent in a notable proportion (10-30%) of various cancer types. This deficiency creates a unique vulnerability that the PRMT5 inhibitor aims to exploit.

The loss of the MTAP-GEN occurs in a variety of tumor species, including those with few treatment options and poor prognosis, such as pancreatic cancer and glioblastoma.

Dominik Rütticher, Head of Research and Early Progress for Oncology at Bayer Pharmaceuticals

Pancreatic cancer, such as, remains a formidable challenge, with a five-year survival rate hovering around 11%, according to the American Cancer Society. Glioblastoma, an aggressive brain cancer, presents similar difficulties in treatment. The potential of Bay3713372 to address these hard-to-treat cancers is a key driver of Bayer’s investment.

Phase 1 Clinical Trials Underway

Bayer has already initiated a phase 1 clinical trial to evaluate the safety and efficacy of Bay3713372. This early-stage trial is crucial for determining the drug’s potential and identifying any potential side effects.

Selective targeting: A Key Advantage

A crucial aspect of this therapeutic approach is its potential for selective targeting. The mechanism of action is designed to effectively attack tumor cells while sparing healthy cells, minimizing potential side effects.This selectivity is a significant advantage in cancer therapy, where minimizing damage to healthy tissues is paramount.

Very promising mechanism of action in which tumor cells can be effectively attacked, but healthy cells were spared.

Jürgen Eckhardt, Pharmaceutical Manager at Bayer

Oncology Pipeline Expansion: A Strategic Imperative

This acquisition underscores Bayer’s commitment to expanding its oncology portfolio. With cancer remaining a leading cause of death worldwide, the development of novel therapies is a critical area of focus for pharmaceutical companies. Bayer’s strategic investment in Bay3713372 reflects this imperative and positions the company to potentially address unmet needs in cancer treatment.